MAPK3 and brain ischemia: On the contrary, methylcobalamin activated the ERK1/2 pathway, whereas ERK1/2 inhibitors diminished its effects in the in vitro and in vivo models and decreased the neuroprotective effects in cerebral ischemia/reperfusion injury [69].